• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原癌基因Evi1与组蛋白甲基转移酶SUV39H1和G9a之间的新型相互作用。

A novel interaction between the proto-oncogene Evi1 and histone methyltransferases, SUV39H1 and G9a.

作者信息

Spensberger Dominik, Delwel Ruud

机构信息

Department of Hematology, Erasmus University Medical Center, Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands.

出版信息

FEBS Lett. 2008 Aug 6;582(18):2761-7. doi: 10.1016/j.febslet.2008.06.056. Epub 2008 Jul 11.

DOI:10.1016/j.febslet.2008.06.056
PMID:18619962
Abstract

The transcription factor ecotropic viral integration site 1 (Evi1) is associated with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in patients due to chromosomal aberration of chromosome 3. Here we show that Evi1 interacts with the histone methyltransferase SUV39H1. The interaction requires the N-terminal part of Evi1 and the H3-specific histone methyltransferase domain, SET, of SUV39H1 without Evi1 having an inhibitory effect on SUV39H1 methyltransferase activity. Presence of SUV39H1 enhances Evi1 transcriptional repression in a dose dependent manner. In addition, Evi1 also interacts with another histone methyltransferase, G9a, but not with SET9. Our data establish an epigenetic role of Evi1 in cell transformation by recruiting higher order chromatin remodeling complexes.

摘要

转录因子嗜亲性病毒整合位点1(Evi1)因3号染色体的染色体畸变而与患者的急性髓性白血病(AML)和骨髓增生异常综合征(MDS)相关。在此我们表明,Evi1与组蛋白甲基转移酶SUV39H1相互作用。这种相互作用需要Evi1的N端部分以及SUV39H1的H3特异性组蛋白甲基转移酶结构域SET,而Evi1对SUV39H1甲基转移酶活性没有抑制作用。SUV39H1的存在以剂量依赖的方式增强Evi1的转录抑制作用。此外,Evi1还与另一种组蛋白甲基转移酶G9a相互作用,但不与SET9相互作用。我们的数据通过招募高阶染色质重塑复合物确立了Evi1在细胞转化中的表观遗传作用。

相似文献

1
A novel interaction between the proto-oncogene Evi1 and histone methyltransferases, SUV39H1 and G9a.原癌基因Evi1与组蛋白甲基转移酶SUV39H1和G9a之间的新型相互作用。
FEBS Lett. 2008 Aug 6;582(18):2761-7. doi: 10.1016/j.febslet.2008.06.056. Epub 2008 Jul 11.
2
EVI1 recruits the histone methyltransferase SUV39H1 for transcription repression.EVI1招募组蛋白甲基转移酶SUV39H1以抑制转录。
J Cell Biochem. 2008 Oct 1;105(2):344-52. doi: 10.1002/jcb.21869.
3
Myeloid transforming protein Evi1 interacts with methyl-CpG binding domain protein 3 and inhibits in vitro histone deacetylation by Mbd3/Mi-2/NuRD.髓系转化蛋白Evi1与甲基化CpG结合域蛋白3相互作用,并在体外抑制Mbd3/Mi-2/NuRD介导的组蛋白去乙酰化作用。
Biochemistry. 2008 Jun 17;47(24):6418-26. doi: 10.1021/bi800267f. Epub 2008 May 24.
4
SIRT1 regulates the histone methyl-transferase SUV39H1 during heterochromatin formation.在异染色质形成过程中,SIRT1调节组蛋白甲基转移酶SUV39H1。
Nature. 2007 Nov 15;450(7168):440-4. doi: 10.1038/nature06268.
5
Regulation of chromatin structure by site-specific histone H3 methyltransferases.位点特异性组蛋白H3甲基转移酶对染色质结构的调控
Nature. 2000 Aug 10;406(6796):593-9. doi: 10.1038/35020506.
6
SUV39H1 interacts with HTLV-1 Tax and abrogates Tax transactivation of HTLV-1 LTR.SUV39H1与人类嗜T淋巴细胞病毒1型(HTLV-1)的Tax蛋白相互作用,并消除Tax对HTLV-1长末端重复序列(LTR)的反式激活作用。
Retrovirology. 2006 Jan 13;3:5. doi: 10.1186/1742-4690-3-5.
7
Catalytic properties and kinetic mechanism of human recombinant Lys-9 histone H3 methyltransferase SUV39H1: participation of the chromodomain in enzymatic catalysis.人重组赖氨酸-9组蛋白H3甲基转移酶SUV39H1的催化特性及动力学机制:色域在酶催化中的作用
Biochemistry. 2006 Mar 14;45(10):3272-84. doi: 10.1021/bi051997r.
8
UXT interacts with the transcriptional repressor protein EVI1 and suppresses cell transformation.UXT与转录抑制蛋白EVI1相互作用并抑制细胞转化。
FEBS J. 2007 Aug;274(15):3960-71. doi: 10.1111/j.1742-4658.2007.05928.x. Epub 2007 Jul 16.
9
SUV39H1 interacts with AML1 and abrogates AML1 transactivity. AML1 is methylated in vivo.SUV39H1与AML1相互作用并消除AML1的转录活性。AML1在体内发生甲基化。
Oncogene. 2003 Aug 14;22(34):5229-37. doi: 10.1038/sj.onc.1206600.
10
EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization.EVI-1 与组蛋白甲基转移酶 SUV39H1 和 G9a 相互作用,进行转录抑制和骨髓永生化。
Leukemia. 2010 Jan;24(1):81-8. doi: 10.1038/leu.2009.202. Epub 2009 Sep 24.

引用本文的文献

1
Oncogene drives acute myeloid leukemia via a targetable interaction with CTBP2.癌基因通过与 CTBP2 的可靶向相互作用驱动急性髓系白血病。
Sci Adv. 2024 May 17;10(20):eadk9076. doi: 10.1126/sciadv.adk9076. Epub 2024 May 15.
2
H3K9 dimethylation safeguards cancer cells against activation of the interferon pathway.H3K9二甲基化可保护癌细胞免受干扰素途径激活的影响。
Sci Adv. 2022 Mar 18;8(11):eabf8627. doi: 10.1126/sciadv.abf8627.
3
EZH2/EHMT2 Histone Methyltransferases Inhibit the Transcription of DLX5 and Promote the Transformation of Myelodysplastic Syndrome to Acute Myeloid Leukemia.
EZH2/EHMT2组蛋白甲基转移酶抑制DLX5的转录并促进骨髓增生异常综合征向急性髓系白血病的转化。
Front Cell Dev Biol. 2021 Aug 2;9:619795. doi: 10.3389/fcell.2021.619795. eCollection 2021.
4
EVI1 dysregulation: impact on biology and therapy of myeloid malignancies.EVI1 失调:对髓系恶性肿瘤的生物学和治疗的影响。
Blood Cancer J. 2021 Mar 22;11(3):64. doi: 10.1038/s41408-021-00457-9.
5
Emerging Roles of PRDM Factors in Stem Cells and Neuronal System: Cofactor Dependent Regulation of PRDM3/16 and FOG1/2 (Novel PRDM Factors).PRDM 因子在干细胞和神经元系统中的新兴作用:共因子依赖性调节 PRDM3/16 和 FOG1/2(新型 PRDM 因子)。
Cells. 2020 Dec 4;9(12):2603. doi: 10.3390/cells9122603.
6
EVI1 as a Prognostic and Predictive Biomarker of Clear Cell Renal Cell Carcinoma.EVI1作为透明细胞肾细胞癌的预后和预测生物标志物
Cancers (Basel). 2020 Jan 28;12(2):300. doi: 10.3390/cancers12020300.
7
-7/7q- syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity.7/7q- 综合征在髓系造血恶性肿瘤中的研究进展:尝试理解这种复杂的疾病实体。
Oncogene. 2015 May 7;34(19):2413-25. doi: 10.1038/onc.2014.196. Epub 2014 Jul 7.
8
SET for life: biochemical activities and biological functions of SET domain-containing proteins.终身设定:SET 结构域蛋白的生化活性和生物学功能。
Trends Biochem Sci. 2013 Dec;38(12):621-39. doi: 10.1016/j.tibs.2013.09.004. Epub 2013 Oct 20.
9
Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention.组蛋白赖氨酸特异性甲基转移酶和去甲基酶在肿瘤发生中的作用:癌症治疗和预防的新靶点。
Curr Cancer Drug Targets. 2013 Jun;13(5):558-79. doi: 10.2174/1568009611313050007.
10
Improved therapeutic effect against leukemia by a combination of the histone methyltransferase inhibitor chaetocin and the histone deacetylase inhibitor trichostatin A.组蛋白甲基转移酶抑制剂沙利度胺和组蛋白去乙酰化酶抑制剂曲古抑菌素 A 联合应用可提高白血病的治疗效果。
J Korean Med Sci. 2013 Feb;28(2):237-46. doi: 10.3346/jkms.2013.28.2.237. Epub 2013 Jan 29.